Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

Administration of Autologous Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).

We will assess the 18-month safety and potential efficacy of autologous MSCs as a therapy for CKD. A total of 10 patients with CKD IV injection of high doses 2×106/kg of autologous MSCs t, which will be derived from biopsies of their bone marrow. Assessments will be performed at 1, 3, 6, 12 and 18 months after cell injection. Changes in Glomerular Filtration Rate (GFR) were evaluated by scan isotope.

Inclusion Criteria:

• Male and Female
• CKD symptoms
• CKD confirmed with serum and urine analysis and GFR 25-60 mL/min/1.73 m2
• Patient's age between 25 - 60 years
• Ability to understand and willingness to sign consent from

Exclusion Criteria:

• Pregnant or lactating
• Basis disease such as diabetes, malignancy and autoimmune
• Unable to follow post-operative exercise regimen or return for evaluations